(234 days)
Not Found
No
The device description details a lateral flow immunoassay based on antigen-antibody reactions, which is a traditional biochemical method. There is no mention of AI, ML, or any computational analysis of the results beyond the visual interpretation of lines. The performance studies are standard for this type of assay and do not involve training or testing AI/ML models.
No.
This device is for the qualitative detection of Benzodiazepine in urine, providing a preliminary analytical test result for screening purposes, not for treatment or therapy.
Yes
Explanation: The device is a 'Benzodiazepine Test' that detects the presence of Benzodiazepine in urine, providing a preliminary result for diagnostic purposes related to drug screening.
No
The device description clearly outlines a physical, lateral flow immunoassay strip that utilizes chemical reactions and capillary action to produce a visual result. This is a hardware-based test, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "detection of Benzodiazepine in urine" and for "qualitative detection of oxazepam { in human urine}". This involves testing a sample taken from the human body (urine) in vitro (outside the body) to gain information about a physiological state (presence of Benzodiazepine).
- Device Description: The description details a "lateral flow immunoassay" that uses a "membrane strip" and "reagents" to perform a chemical reaction with the urine sample. This is a typical description of an in vitro diagnostic test.
- Performance Studies: The performance studies involve testing "samples" (urine specimens) and comparing the results to other diagnostic methods (Syva EMIT-II and GC/MS). This is characteristic of the validation process for an IVD.
- Predicate Device: The mention of a "Predicate Device" with a K number (K990099) is a strong indicator that this device is being submitted for regulatory clearance as an IVD, as predicate devices are used to demonstrate substantial equivalence to legally marketed IVDs.
Therefore, based on the provided information, the 'RapidOne' - Benzodiazepine Test clearly fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
'RapidOne' - Benzodiazepine Test is used for the qualitative detection of oxazepam in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas chromatography/mass spectrometry (GC/MS).
'RapidOne' - Benzodiazepine Test is a one-step, lateral flow immunoassay for the detection of Benzodiazepine in urine. 'RapidOne' - Benzodiazepine Test is intended for use in the qualitative detection of : oxazepam in human urine at 300 ng/m.
'RapidOne' - Benzodiazepine Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).
'RapidOne' - Benzodiazepine Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Product codes (comma separated list FDA assigned to the subject device)
JXM
Device Description
The assay employed in the 'RapidOne' - Benzodiazepine Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which anti-amphetamine monoclonal antibody has been immobilized. A colloidal gold-BSAamphetamine complex is dried on a reagent pad. In the absence of any drug in the urine sample, the colloidal gold-complex moves with the urine by capillary action to contact the immobilized drug antibody. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
professional use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
'RapidOne'-Benzodiazepine Test was compared to 'Instacheck' Drug Screen-Benzodiazepine Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 310 ng/ml to 10000 ng/ml, to be positive.
Reproducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 225 | 40 | 32/40 neg | >80% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3170 Benzodiazepine test system.
(a)
Identification. A benzodiazepine test system is a device intended to measure any of the benzodiazepine compounds, sedative and hypnotic drugs, in blood, plasma, and urine. The benzodiazepine compounds include chlordiazepoxide, diazepam, oxazepam, chlorzepate, flurazepam, and nitrazepam. Measurements obtained by this device are used in the diagnosis and treatment of benzodiazepine use or overdose and in monitoring levels of benzodiazepines to ensure appropriate therapy.(b)
Classification. Class II (special controls). A benzodiazepine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510(k) Summary
| Submitter's Name/Address: | Contact Person: |
|---|---|
| American Bio Medica Corporation | |
| 300 Fairview Avenue | |
| Hudson, N.Y. 12534 | Henry Wells |
| Vice President of Product | |
| Development | |
| Phone: 518-822-8882 | |
| Fax: 518-822-0391 | |
| Date of Preparation of this Summary: | August 4, 1999 |
| Device Trade of Proprietary Name: | 'RapidOne'-Benzodiazepine Test |
| Device Common/Usual Name or | |
| Classification Name: | Benzodiazepine test system |
| Classification Number/Class | 21 C.F.R. § 862.3170 (Class II) |
This 510(k) Summary is being submitted in accordance with the requirements of 21 CFR 807.92.
The assigned 510(k) number is: _ K 992720
Predicate Device: Forefront Diagnostics, Inc. 'Instacheck' Drug Screen -Benzodiazepine Test (510(k) No.K990099.)
Test Description:
The assay employed in the 'RapidOne' - Benzodiazepine Test is based on the same principle of highly specific reaction between antigens and antibodies.
This assay is a one-step, immunoassay in which a specially labeled drug (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on the antibody. The test device consists of a membrane strip onto which anti-amphetamine monoclonal antibody has been immobilized. A colloidal gold-BSAamphetamine complex is dried on a reagent pad. In the absence of any drug in the urine sample, the colloidal gold-complex moves with the urine by capillary action to contact the immobilized drug antibody. An antibody-antigen reaction occurs forming a visible line in the 'test' area. The formation of a visible line in the test area occurs when the test is negative.
When drug is present in the urine sample, the drug or metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-antibody complex. If sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the labeled antibody to the drug
1
conjugate. An absence of a color band (line) in the test area is indicative of a positive result.
A control band (line), comprised of a different antibody/antigen reaction, is present on the membrane strip. The control line is not influenced by the presence of absence of drug in the urine, and therefore, should be present in all reactions.
A negative urine will produce two colored bands, and a positive sample will produce only one band.
IntendedUse:
'RapidOne' - Benzodiazepine Test is used for the qualitative detection of oxazepam in human urine. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas chromatography/mass spectrometry (GC/MS).
Performance Characteristics:
'RapidOne' - Benzodiazepine Test will detect 300 ng/ml of oxazepam in urine.
'RapidOne'-Benzodiazepine Test was compared to 'Instacheck' Drug Screen-Benzodiazepine Test. Ninety (90) samples were selected for evaluation, fifty (50) of which were found to be drug-free and forty (40) tested as positive by Syva EMIT-II. The forty positive specimens were confirmed and quantified by GC/MS. Both immunoassays correctly identified all of the specimens which contained no drug as negative and determined the 40 drug-containing specimens, ranging in concentration of 310 ng/ml to 10000 ng/ml, to be positive.
Reproducibility was evaluated using control urines containing concentrations above and below the stated cut-off. Negative urines were also used. Each sample, at each concentration of analyte, was tested 4 times, twice daily, for 5 days.
| Conc. (ng/ml) | # | Result | Precision |
|---|---|---|---|
| 0 | 40 | 40/40 neg | >99% |
| 225 | 40 | 32/40 neg | >80% |
| 300 | 40 | 40/40 pos | >99% |
| 375 | 40 | 40/40 pos | >99% |
Conclusion:
'RapidOne'-Benzodiazepine Test is substantially equivalent to'Instacheck' -- Drug Screen - Benzodiazepine Test
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of an eagle or bird-like figure, represented by three curved lines that suggest the shape of a bird in flight.
Public Health Service
3 2000 APR
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Henry Wells, Ph.D. Vice President of Product Development American Bio Medica Corporation 122 Smith Road Kinderhook, New York 12106
Re: K992720
Trade Name: 'RapidOne' - Benzodiazepine Test Regulatory Class: II Product Code: JXM Dated: February 14, 2000 Received: February 15, 2000
Dear Dr. Wells:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Toutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1_ of l
16992720 510(k) Number (if known):
'RapidOne' - Benzodiazepine Test Device Name:
Indications For Use:
'RapidOne' - Benzodiazepine Test is a one-step, lateral flow immunoassay for the detection of Benzodiazepine in urine. 'RapidOne' - Benzodiazepine Test is intended for use in the qualitative detection of : oxazepam { in human urine at 300 ng/m}.
'RapidOne' - Benzodiazepine Test is intended for professional use. It is not intended for over the counter sale to non-professionals. The assay is easy to perform, but should not be used without proper supervision. This immunoassay is a simplified qualitative screening method that provides only a preliminary result for use in determining the need for additional or confirmatory testing, i.e., gas-chromatography/mass spectrometry (GC/MS).
'RapidOne' - Benzodiazepine Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a more confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.
Dean Cooph
(Division Sign-Off)
ivision of C
$10(k) Numt
Laboratory Devices
K992720
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use